355 related articles for article (PubMed ID: 34461214)
1. Improving temozolomide biopharmaceutical properties in glioblastoma multiforme (GBM) treatment using GBM-targeting nanocarriers.
Delello Di Filippo L; Hofstätter Azambuja J; Paes Dutra JA; Tavares Luiz M; Lobato Duarte J; Nicoleti LR; Olalla Saad ST; Chorilli M
Eur J Pharm Biopharm; 2021 Nov; 168():76-89. PubMed ID: 34461214
[TBL] [Abstract][Full Text] [Related]
2. Brain Targeting by Liposome-Biomolecular Corona Boosts Anticancer Efficacy of Temozolomide in Glioblastoma Cells.
Arcella A; Palchetti S; Digiacomo L; Pozzi D; Capriotti AL; Frati L; Oliva MA; Tsaouli G; Rota R; Screpanti I; Mahmoudi M; Caracciolo G
ACS Chem Neurosci; 2018 Dec; 9(12):3166-3174. PubMed ID: 30015470
[TBL] [Abstract][Full Text] [Related]
3. Lumefantrine, an antimalarial drug, reverses radiation and temozolomide resistance in glioblastoma.
Rajesh Y; Biswas A; Kumar U; Banerjee I; Das S; Maji S; Das SK; Emdad L; Cavenee WK; Mandal M; Fisher PB
Proc Natl Acad Sci U S A; 2020 Jun; 117(22):12324-12331. PubMed ID: 32409605
[TBL] [Abstract][Full Text] [Related]
4. Intranasal Delivery of Temozolomide-Conjugated Gold Nanoparticles Functionalized with Anti-EphA3 for Glioblastoma Targeting.
Wang L; Tang S; Yu Y; Lv Y; Wang A; Yan X; Li N; Sha C; Sun K; Li Y
Mol Pharm; 2021 Mar; 18(3):915-927. PubMed ID: 33417456
[TBL] [Abstract][Full Text] [Related]
5. miR-1268a regulates ABCC1 expression to mediate temozolomide resistance in glioblastoma.
Li Y; Liu Y; Ren J; Deng S; Yi G; Guo M; Shu S; Zhao L; Peng Y; Qi S
J Neurooncol; 2018 Jul; 138(3):499-508. PubMed ID: 29876787
[TBL] [Abstract][Full Text] [Related]
6. Dual-targeted delivery of temozolomide by multi-responsive nanoplatform via tumor microenvironment modulation for overcoming drug resistance to treat glioblastoma.
Chen X; Zheng Y; Zhang Q; Chen Q; Chen Z; Wu D
J Nanobiotechnology; 2024 May; 22(1):264. PubMed ID: 38760771
[TBL] [Abstract][Full Text] [Related]
7. Dual-targeting immunoliposomes using angiopep-2 and CD133 antibody for glioblastoma stem cells.
Kim JS; Shin DH; Kim JS
J Control Release; 2018 Jan; 269():245-257. PubMed ID: 29162480
[TBL] [Abstract][Full Text] [Related]
8. Modulating lncRNA SNHG15/CDK6/miR-627 circuit by palbociclib, overcomes temozolomide resistance and reduces M2-polarization of glioma associated microglia in glioblastoma multiforme.
Li Z; Zhang J; Zheng H; Li C; Xiong J; Wang W; Bao H; Jin H; Liang P
J Exp Clin Cancer Res; 2019 Aug; 38(1):380. PubMed ID: 31462285
[TBL] [Abstract][Full Text] [Related]
9. 20(S)-ginsenoside-Rg3 reverses temozolomide resistance and restrains epithelial-mesenchymal transition progression in glioblastoma.
Chen Z; Wei X; Shen L; Zhu H; Zheng X
Cancer Sci; 2019 Jan; 110(1):389-400. PubMed ID: 30431207
[TBL] [Abstract][Full Text] [Related]
10. Targeting NFE2L2, a transcription factor upstream of MMP-2: A potential therapeutic strategy for temozolomide resistant glioblastoma.
Rajesh Y; Biswas A; Kumar U; Das S; Banerjee I; Banik P; Bharti R; Nayak S; Ghosh SK; Mandal M
Biochem Pharmacol; 2019 Jun; 164():1-16. PubMed ID: 30885764
[TBL] [Abstract][Full Text] [Related]
11. Exploring temozolomide encapsulated PEGylated liposomes and lyotropic liquid crystals for effective treatment of glioblastoma: in-vitro, cell line, and pharmacokinetic studies.
Waghule T; Laxmi Swetha K; Roy A; Narayan Saha R; Singhvi G
Eur J Pharm Biopharm; 2023 May; 186():18-29. PubMed ID: 36924995
[TBL] [Abstract][Full Text] [Related]
12. miR-140 targeting CTSB signaling suppresses the mesenchymal transition and enhances temozolomide cytotoxicity in glioblastoma multiforme.
Ho KH; Cheng CH; Chou CM; Chen PH; Liu AJ; Lin CW; Shih CM; Chen KC
Pharmacol Res; 2019 Sep; 147():104390. PubMed ID: 31398406
[TBL] [Abstract][Full Text] [Related]
13. miR-126-3p sensitizes glioblastoma cells to temozolomide by inactivating Wnt/β-catenin signaling via targeting SOX2.
Luo W; Yan D; Song Z; Zhu X; Liu X; Li X; Zhao S
Life Sci; 2019 Jun; 226():98-106. PubMed ID: 30980849
[TBL] [Abstract][Full Text] [Related]
14. Riluzole enhances the antitumor effects of temozolomide via suppression of MGMT expression in glioblastoma.
Yamada T; Tsuji S; Nakamura S; Egashira Y; Shimazawa M; Nakayama N; Yano H; Iwama T; Hara H
J Neurosurg; 2020 Mar; 134(3):701-710. PubMed ID: 32168477
[TBL] [Abstract][Full Text] [Related]
15. Overcoming the Blood-Brain Tumor Barrier with Docetaxel-Loaded Mesoporous Silica Nanoparticles for Treatment of Temozolomide-Resistant Glioblastoma.
Hsu TI; Chen YP; Zhang RL; Chen ZA; Wu CH; Chang WC; Mou CY; Chan HW; Wu SH
ACS Appl Mater Interfaces; 2024 May; 16(17):21722-21735. PubMed ID: 38629735
[TBL] [Abstract][Full Text] [Related]
16. Thioridazine inhibits autophagy and sensitizes glioblastoma cells to temozolomide.
Johannessen TC; Hasan-Olive MM; Zhu H; Denisova O; Grudic A; Latif MA; Saed H; Varughese JK; Røsland GV; Yang N; Sundstrøm T; Nordal A; Tronstad KJ; Wang J; Lund-Johansen M; Simonsen A; Janji B; Westermarck J; Bjerkvig R; Prestegarden L
Int J Cancer; 2019 Apr; 144(7):1735-1745. PubMed ID: 30289977
[TBL] [Abstract][Full Text] [Related]
17. Biodegradable wafers releasing Temozolomide and Carmustine for the treatment of brain cancer.
Shapira-Furman T; Serra R; Gorelick N; Doglioli M; Tagliaferri V; Cecia A; Peters M; Kumar A; Rottenberg Y; Langer R; Brem H; Tyler B; Domb AJ
J Control Release; 2019 Feb; 295():93-101. PubMed ID: 30605703
[TBL] [Abstract][Full Text] [Related]
18. Liposomal temozolomide drug delivery using convection enhanced delivery.
Nordling-David MM; Yaffe R; Guez D; Meirow H; Last D; Grad E; Salomon S; Sharabi S; Levi-Kalisman Y; Golomb G; Mardor Y
J Control Release; 2017 Sep; 261():138-146. PubMed ID: 28666727
[TBL] [Abstract][Full Text] [Related]
19. Involvement of Intracellular Cholesterol in Temozolomide-Induced Glioblastoma Cell Death.
Yamamoto Y; Sasaki N; Kumagai K; Takeuchi S; Toyooka T; Otani N; Wada K; Narita Y; Ichimura K; Namba H; Mori K; Tomiyama A
Neurol Med Chir (Tokyo); 2018 Jul; 58(7):296-302. PubMed ID: 29899179
[TBL] [Abstract][Full Text] [Related]
20. MicroRNA-101 reverses temozolomide resistance by inhibition of GSK3β in glioblastoma.
Tian T; Mingyi M; Qiu X; Qiu Y
Oncotarget; 2016 Nov; 7(48):79584-79595. PubMed ID: 27792996
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
